Friday, July 10, 2026

Drug profile · INN

sonidegib phosphate

sonidegib phosphate (ODOMZO) is a smoothened homolog inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — sonidegib phosphate
US status
approved
Class
Route
ORAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

sonidegib phosphate (ODOMZO) is a smoothened homolog inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sonidegib phosphate
Brand ODOMZO
Mechanism Smoothened homolog inhibitor
Target Protein smoothened
Route ORAL
Formulation CAPSULE

Mechanism of action

Smoothened homolog inhibitor

Primary target: Protein smoothened

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 1634 Phase 2 · Ningbo Cancer Hospital · Newly Diagnosed Medulloblastoma
  2. Odomzo 200 mg hard capsules Phase 2 · Telethon Foundation · locally advanced basal cell carcinoma

Related & competitor drugs

  1. glasdegib maleate Smoothened homolog antagonist
  2. vismodegib Antineoplastic and immunomodulating agents (L01)
  3. glasdegib Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is sonidegib phosphate?

sonidegib phosphate (ODOMZO) is a smoothened homolog inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sonidegib phosphate?

ODOMZO is a marketed brand name for sonidegib phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sonidegib phosphate?

sonidegib phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.